ALXO 株価推移チャート
ALXO 財務
ALX Oncology Holdings Inc
$2.08
11.22%
$0.2
終値： May 08, 16:00:00 GMT-4
$1.97
-5.28%
$-0.11
アフターマーケット：May 08, 20:00:00 GMT-4
戻る
ALX Oncology Holdings Inc (ALXO) 財務
主要データ
前終値
$1.87
始値
$1.89
当日レンジ
$1.76 - $2.1
52週レンジ
$0.404 - $2.66
取引高
998.6K
平均取引高
752.6K
配当利回り
--
1株当たり利益(TTM)
-1.90
時価総額
$259.2M
ALXOとは何ですか？
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 43 full-time employees. The company went IPO on 2020-07-17. The firm's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
